Jayson dining with friends Jayson dining with friends

About CABENUVA

Explore the results of our clinical studies

Jayson
Stays undetectable with
CABENUVA
Results may vary.

Jayson
Stays undetectable with
CABENUVA
Results may vary.

CAN CABENUVA KEEP ME UNDETECTABLE? 

Checkmark icon

Long-acting CABENUVA is proven to help keep people undetectable.*

CABENUVA was tested in 3 clinical studies, involving more than 2,200 undetectable adults who either switched or continued their HIV regimen.

  • In 2 studies, people received once-monthly CABENUVA or continued their daily pill regimen
  • In the other study, people received CABENUVA injections every other month or once a month
  • Those who switched to CABENUVA
  • Those who continued on their current daily pill regimen

The studies included a diverse range of people across age, race, and gender, including transgender individuals.

At Week 48 in all studies:

  • 9 out of 10 people remained undetectable, whether they were on daily HIV pills or CABENUVA
  • Less than 2% of people did not remain undetectable (primary endpoint)

Results were consistent:

  • With both once-monthly and every-other-month regimens
  • Whether or not people took starter pills before beginning injections
  • Across a diverse range of ages, races, and genders, including transgender people
  • After 96 weeks

CABENUVA was also tested in people 12 years and older who weigh at least 77 lbs (35 kg).

  • Those who switched to CABENUVA
  • Those who continued on their current daily pill regimen

The studies included a diverse range of people across age, race, and gender, including transgender individuals.

Undetectable means the amount of HIV in the blood is below the level that can be measured by a lab test (less than 50 copies/mL). Results may vary.

Daily pill regimens contained dolutegravir and 2 nucleoside reverse transcriptase inhibitors (NRTIs) or 2 NRTIs plus a protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or integrase strand transfer inhibitor (INSTI).

Undetectable means the amount of HIV in the blood is below the level that can be measured by a lab test (less than 50 copies/mL).

Results may vary.

WHAT WERE THE SIDE EFFECTS?

Safety icon

The most common side effects reported in all clinical studies were injection-site reactions.

  • 75% to 83% of patients experienced injection-site reactions.

Overall, injection-site reactions lasted about 3 days and were mostly mild to moderate.

Injection-site reactions were reported less often the longer people were on treatment.§

Aside from injection-site reactions, the most common side effects to occur in less than 9% of people were:

  • Fever
  • Tiredness
  • Headache
  • Muscle or bone pain
  • Nausea
  • Sleep problems
  • Dizziness
  • Rash

Less than 4% of people on CABENUVA stopped treatment due to any side effect.||

These are not the only side effects of CABENUVA. For more information, see the Risks & Side Effects page. Always tell your doctor if you experience any side effect.

Results may vary.

Injection-site reactions include pain, tenderness, hardened mass or lump, swelling, redness, itching, bruising, and warmth at the injection site.

§The true rate of injection-site reactions over time may be underestimated, as symptoms that occurred may not have been reported during the study.

||4% of people on once-monthly CABENUVA; 2% of people on every-other-month CABENUVA.

 

DID PEOPLE PREFER LONG-ACTING CABENUVA?

9 out of 10 people who switched to CABENUVA preferred once-a-month injections over their previous daily pill regimen†§¶

Preference 9 out of 10

9 out of 10 people preferred the long-acting CABENUVA regimen they switched to over their previous regimen.†¶#**

In a survey conducted during clinical studies, people were asked how they felt about their treatment, including which one they preferred. The results are their opinions and don’t imply clinical effectiveness.

Could the same be true for you? 
Find out how to have the CABENUVA conversation with your doctor.

88% of people said they preferred once-monthly CABENUVA over their previous daily HIV pills, 2% preferred daily HIV pills, and 10% did not respond to the survey question.
#94% of people with previous CABENUVA experience said they preferred injections every other month over their previous once-monthly injections or daily starter pills, 3% preferred once-monthly injections, 2% preferred daily starter pills, and 1% reported no preference.
**98% of people with no previous CABENUVA use preferred injections every other month over daily starter pills, 1% preferred daily starter pills, and <1% reported no preference.

"The first time there was some discomfort, I was a little sore after. The second time was different."

Jayson

Stays undetectable
with CABENUVA

Results may vary.

Photograph of Jayson

COULD SWITCHING
TO
CABENUVA
BE
RIGHT FOR ME?

$ctaSubText1

WANT MORE INFORMATION?

$ctaSubText2

Learn about other people’s experiences on CABENUVA

CBRWCNT240027